WuXi Biologics sees share capital rise from option exercises

For August 2025, WuXi Biologics (Cayman) Inc. reported an increase of 927,380 in its issued ordinary shares, bringing the total to 4,071,440,456 shares. This increase was solely attributable to the exercise of Pre-IPO Share Options under various tranches, raising $201,544.69 from these exercises.

The Pre-IPO Share Option Scheme saw multiple exercises throughout the month, with notable tranches including options granted in January, March, August, and November of 2016, and March and May of 2017. Following these exercises, a total of 86,675,251, 550,825, 3,955,100, 1,119,345, 27,972,223, and 1,204,275 options remain outstanding for each respective grant date.

Additionally, the company noted that 23,180,000 ordinary shares were repurchased on 8 and 9 July 2025 for cancellation, but these shares have not yet been cancelled as of 31 August 2025. No further share options can be granted under the Pre-IPO Share Option Scheme, and the total authorised/registered share capital remained at $50,000.